# Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

> **NCT02546284** · PHASE1 · COMPLETED · sponsor: **Humanigen, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia (CMML)

## Interventions

- **DRUG:** lenzilumab

## Key facts

- **NCT ID:** NCT02546284
- **Lead sponsor:** Humanigen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546284, "Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02546284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*